In the ILD-GC Set, the categories of anticancer medications administered from 30 days before to the day before ILD onset were as follows: programmed cell death protein 1 (PD-1) inhibitors (3 cases), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (2 cases), anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) (1 case), and cytotoxic agents (4 cases). The gene discussed is ALK; the disease is interstitial lung disease.